Company intelligence / Profile preview

Sinntaxis

Ownership: Private
Development stage: Preclinical

Overview

Sinntaxis focuses on developing novel therapeutics that enhance the recovery of brain functions after stroke and other brain injuries. The company’s lead programs involve negative allosteric modulators (NAMs) of the mGlu5 receptor, with preclinical data showing restoration of somatosensory function post-stroke. Clinical candidates such as dipraglurant and AZD2066 have demonstrated safety in previous trials for other indications and are now being repositioned for post-stroke/brain injury functional recovery[1][5][6].

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Addex Therapeutics (collaboration on dipraglurant development for brain injury/stroke)[1][6]Acturum AB/AstraZeneca legacy asset licensing agreement for AZD2066[5]

Beyond the preview

Go deeper on Sinntaxis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sinntaxis.

Explore the full profile